Drugs / Autologous CD19-CD20-NKG2D-nsBicephali CAR-T
Autologous CD19-CD20-NKG2D-nsBicephali CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07555561 | Sep 2026 → Dec 2027 | central nervous system non-hodgkin lymphoma | Beijing Boren Hospital | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19-CD20-NKG2D-nsBicephali CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07555561 ↗ |
| Known as | Autologous CD19-CD20-NKG2D-nsBicephali CAR-T Cell Injection | “The product name stated in the protocol is Autologous CD19-CD20-NKG2D-nsBicephali CAR-T Cell Injection.” NCT07555561 ↗ |
| Action | Deplete | “directly eliminate CD19/CD20-positive lymphoma cells” NCT07555561 ↗ |
| Modality | Cell therapy | “generate autologous CAR-T cells for reinfusion” NCT07555561 ↗ |